

Natpara (parathyroid hormone)

Initial Coverage Criteria:

1. Patient must be using in combination with an active form of vitamin D and calcium; and,
2. Patient is 18 years of age or older; and,
3. Patient is diagnosed with hypoparathyroidism, documented by biochemical evidence of hypocalcemia and concomitant serum intact parathyroid hormone (PTH) concentrations below the lower limit of the normal laboratory reference range on 2 test dates at least 21 days apart within the past 12 months; and,
4. Patient has a history of severe symptoms (e.g. paralysis) requiring hospitalization at least once within the past year; **OR**
5. The patient meets all of the following criteria:
 - a. History of hypoparathyroidism for at least 18 months; and
 - b. No known history of hypoparathyroidism resulting from an activating mutation in the CaSR gene or impaired responsiveness to PTH (pseudohypoparathyroidism); and
 - c. No disease that might increase the risk of osteosarcoma; and
 - d. Adherent to vitamin D metabolite/analog therapy with calcitriol =0.5 g per day or alphacalcidol =0.50 g per day for at least three months prior to the request; and
 - e. Adherent to a regimen of supplemental oral calcium treatment = 1000 mg per day for at least three months prior to the request; and
 - f. Serum magnesium levels within laboratory normal limits; and
 - g. Serum 25-hydroxyvitamin D concentration above the lower limit of the normal laboratory reference range; and
 - h. Creatinine clearance > 30 mL/min on two separate measurements **OR** creatinine clearance > 60 mL/min **AND** serum creatinine < 1.5 mg/dL.



Reauthorization/Renewal Criteria:

1. Patient continues to meet the criteria above; and,
2. Patient has been seen in the last 12 months by their prescriber; and,
3. Patient has been adherent to their treatment plan.

Authorizations will be for 12 months.